CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to PRAX

20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

Phase 3
Praxis Precision Medicines, Inc. (PRAX)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Focal Seizure

View Full Landscape
Drug Information

Target Indication

Focal Seizure

Clinical Trial

NCT06999902

Last updated: 6/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.